News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology

Articles by Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology

Radium-223 in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Genetic Testing in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Trending on OncLive

Unpacking the FDA Approvals That Reshaped Cancer Care in 2025

Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma

Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome

FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC

NALIRIFOX Remains Effective Despite Dose Modification in First-Line PDAC